The key takeaway is that BPC-157 is pleiotropic
You may also like Product Description CJC-1295 Without DAC + Ipamorelin CJC-1295 Without DAC + Ipamorelin is the most widely studied dual-receptor growth hormone secretagogue combination in pre-clinical research pairing Modified GRF (1-29), a tetra-substituted GHRH receptor agonist, with Ipamorelin, the first selective GHS-R1a (ghrelin receptor) agonist, to simultaneously engage two entirely distinct and complementary pituitary signalling pathways
Each 0.01mL (1 unit on a U-100 insulin syringe) contains approximately 267mcg of total peptide
Preservative: 0.9% Benzyl Alcohol
What this means for you right now: BPC-157 and TB-500 are currently available through licensed compounding pharmacies under clinician supervision Thymosin Alpha-1 has a longer regulatory history and a more established compounding track record Sourcing from unregulated vendors carries real safety risks contamination, misdosing, and no quality control We've covered the full regulatory picture in detail here: PCAC Peptide Review 2026: What the July Advisory Panel Decision Means for BPC-157, TB-500, and Thymosin Alpha-1 What a Clinician-Supervised Long COVID Peptide Protocol Looks Like A responsible protocol starts with assessment not assumption
Avoid taking anti-inflammatory medications such as aspirin and ibuprofen for a few days before the procedure
